[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].

Takeshi Sunami, Jun Tauchi, Katsuya Sakashita, Kiyotaka Yukimoto, Ryugo Sawada, Kazutsugu Sakamoto

Index: Gan To Kagaku Ryoho. 41(5) , 649-51, (2014)

Full Text: HTML

Abstract

We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP. A 67-year-old man was diagnosed with multiple liver metastases one year after distal gastrectomy+D2 dissection for gastric cancer. S-1/CDDP was given as the first-line treatment, followed by paclitaxel (PTX), irinotecan (CPT-11), and docetaxel (DOC). The tumor in the anterior segment of the liver was resistant to all of these chemotherapies except for PTX, which is why the regimens were changed. However, this tumor shrank and achieved stable disease status for four months after capecitabine/CDDP therapy given as fifth-line treatment. Our case suggests that S-1 and capecitabine do not always exhibit cross-resistance. Therefore, capecitabine may be effective in S-1-pretreated patients, and vice versa.